Driftstatus

Nyheter i Janusmed

Janusmed

Driftstatus

Nyheter i Janusmed

YENTREVE (Enterokapsel, hård), terbinafin
  • YENTREVE (Enterokapsel, hård)
  • terbinafin
Rensa sökning

7/17/2025

Janusmed interaktioner

Interaktioner

Startsida interaktioner

Aktuellt

Användarhandledning

E-utbildning

CYP3A4-hämmare/inducerare

FAQ

Skriv ut

Administreringssätt

Skriv ut

1 interaktion mellan valda läkemedel
Lägg till
Rensa tillval
Läkemedel / substans
Interaktioner
terbinafin (Enteral och parenteral)

59

YENTREVE (Enterokapsel, hård)
duloxetin (Enteral peroral)

160

C0 C0
C0 C0

duloxetin - terbinafin

duloxetin - terbinafin

Klass : C0

Visa all info

Skriv ut

Kontakta oss

  1. Duloxetine (Cymbalta). Eli Lilly. EPAR scientific discussion. 2006.

  2. Duloxetine (Yentreve). Eli Lilly. EPAR Scientific discussion. 2006.

  3. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther. 1999;65:465-72.

  4. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 1999;27:770-5.

  5. Cai WM, Chen B, Ling SS, Zhang YD. Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. Br J Clin Pharmacol. 2001;51:107-8.

  6. Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002;42:1211-8.

  7. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-7.

  1. Duloxetine (Cymbalta). Eli Lilly. EPAR scientific discussion. 2006.
  2. Duloxetine (Yentreve). Eli Lilly. EPAR Scientific discussion. 2006.
  3. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther. 1999;65:465-72.
  4. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 1999;27:770-5.
  5. Cai WM, Chen B, Ling SS, Zhang YD. Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. Br J Clin Pharmacol. 2001;51:107-8.
  6. Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002;42:1211-8.
  7. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-7.